A pH-responsive chiral mesoporous silica nanoparticles for delivery of doxorubicin in tumor-targeted therapy

Gou, Kaijun; Wei, Xin; Lv, Jinying; Ma, Zihao; Yang, Juqin; Zhao, Lin; Cheng, Ying; Chen, Xuchun; Zhou, Rui; Li, Heran

doi:10.1016/j.colsurfb.2022.113027

Cited by 14 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the pH shift from the DMEM medium to the cancer cells' internal environment, which contained other reducing reagents, enabled the release of DOX. These findings align with previous literature reports [31,32]. However, in our case, the DOX release was enhanced by the redox reaction that cleaves the disulfide bonds.…”

Section: Cellular Uptakesupporting

confidence: 93%

Disulfide-Modified Mesoporous Silica Nanoparticles for Biomedical Applications

Venedicto

Carrier

et al. 2023

Crystals

View full text Add to dashboard Cite

Mesoporous silica nanoparticles (MSNs) are highly porous carriers used in drug and gene delivery research for biomedical applications due to their high surface area, narrow particle size distribution, and low toxicity. Incorporating disulfide (SS) bonds into the walls of MSNs (MSN-SSs) offers a dual pathway for drug release due to the pore delivery and collapsing porous structure after cellular engulfment. This study explores the effect of embedding disulfide bonds into MSNs through various structural and biological characterization methods. Raman spectroscopy is employed to detect the SS bonds, SEM and TEM for morphology analyses, and a BET analysis to determine the required amount of SSs for achieving the largest surface area. The MSN-SSs are further loaded with doxorubicin, an anticancer drug, to assess drug release behavior under various pH conditions. The MSN-SS system demonstrated an efficient pH-responsive drug release, with over 65% of doxorubicin released under acidic conditions and over 15% released under neutral conditions. Cleaving the SS bonds using dithiothreitol increased the release to 94% in acidic conditions and 46% in neutral conditions. Biocompatibility studies were conducted using cancer cells to validate the engulfment of the nanoparticle. These results demonstrate that MSN-SS is a feasible nanocarrier for controlled-release drug delivery.

show abstract

Section: Cellular Uptakesupporting

confidence: 93%